The 2025 European Drug Report, released by the European Union Drugs Agency (EUDA), offers a grim diagnosis of a continent that is not just losing the war on drugs, but in some cases appears to have surrendered altogether.
While the EU likes to trumpet its evidence-based and health-centred approach to narcotics, the results speak louder than policy papers. Cocaine use is at record highs, synthetic drug production is thriving in Belgium and the Netherlands, and potent new substances continue to evade control systems. All the while, young Europeans are being funnelled into a culture where recreational drug use is increasingly normalised and lightly policed.
What emerges most starkly from this year’s report is the deepening entrenchment of synthetic drugs in the European market. Amphetamines, MDMA, methamphetamines and a growing list of unclassifiable designer drugs are no longer fringe problems—they are central fixtures of the drug trade. Behind the scenes, criminal syndicates with industrial-scale labs and global networks operate with chilling efficiency. The report makes plain that Europe is now not just a consumer but also a key global producer of synthetic substances.
There is also a sobering reality to the cocaine figures. For years, Brussels assured citizens that the cocaine problem was manageable, limited largely to affluent pockets of urban nightlife. Not anymore. The EUDA report shows that cocaine is not only more available than ever, but its price has dropped and its purity remains high. In cities like Antwerp, Hamburg and Barcelona, authorities are overwhelmed by the volume of cocaine trafficking through ports, often concealed in banana crates and bulk shipments from Latin America.
Policing has failed to keep pace. If anything, the scale of seizures—boasting record-breaking tonnage—only confirms the enormity of the trade. One can seize 100 tonnes of cocaine and still barely dent the supply. The economic incentives are simply too vast, and the infrastructure of the trade too robust, for traditional enforcement to achieve lasting success.
Even cannabis, long painted as a ‘soft’ drug, has become a source of concern. The strength of cannabis on Europe’s streets has increased dramatically in recent years. Highly potent varieties and extracts now dominate the market, many of them cultivated in illicit grow-houses hidden in quiet suburban neighbourhoods. Meanwhile, political calls for legalisation—especially in Germany and parts of the Netherlands—risk sending a confusing message to young people about the risks of early and frequent use.
Underlying all this is a public health time bomb. Hospital admissions related to drug overdoses and psychiatric episodes are rising. Emergency services are reporting higher incidences of poisoning from synthetic cannabinoids and opioids. And the appearance of nitazenes—ultra-potent synthetic opioids sometimes deadlier than fentanyl—has set off alarm bells across Europe’s health ministries.
Perhaps the most frustrating part of this whole picture is the lack of political urgency. While the EUDA report is a meticulously assembled document, replete with statistics and thoughtful recommendations, the broader Brussels machinery remains sluggish. Europe has long championed a harm-reduction model focused on treatment, prevention, and education. But that model, admirable in theory, now appears dangerously inadequate against the tide of industrialised narcotics and multi-billion-euro trafficking operations.
There is also a tendency, especially in Western Europe, to treat drug use as a cultural inevitability rather than a societal failure. Decriminalisation is debated endlessly, and user-centred services like supervised injection rooms are often treated as endpoints rather than interim measures. Little thought is given to how these policies play out in communities that already struggle with unemployment, youth disenfranchisement, and weakened local policing.
To be fair, the EUDA is not blind to these challenges. It has consistently highlighted the fragmentation of Europe’s drug response, the need for better cross-border coordination, and the threat posed by synthetic drugs. But this year’s report should serve as a clarion call: Europe needs a far more robust and assertive approach.
That means increased investment in intelligence-led policing, especially at key port and airport hubs. It means reversing the trend of slashed budgets for anti-narcotics units. And it means confronting the uncomfortable reality that parts of Europe are becoming narcotics transit zones for the world.
Brussels has often spoken about resilience and unity in the face of challenges. The drug crisis is no different. Without decisive action, today’s report won’t be a warning—it will be a post-mortem.
____________________________________________________________________________________________________________________
Read Also: BRUSSELS DRUGS WARS: HAVE THE POLICE LOST CONTROL OF THE STREETS?
Three shootings on three consecutive mornings. Rising Violence in the Belgian Capital Raises Questions Over Law Enforcement’s Grip on Security.
____________________________________________________________________________________________________________________
